The global sales of advanced at-home biomarker testing are estimated to be worth USD 1,099.5 million in 2024 and are anticipated to reach a value of USD 2,255.7 million by 2034. Sales are projected to rise at a CAGR of 7.5% over the forecast period between 2024 and 2034. The revenue generated by advanced at-home biomarker testing in 2023 was USD 1,024.0 million.
The advanced at home-use biomarker testing market is emerging and strengthening with an impressive demand for convenience and personalized healthcare solutions. These test kits allow individuals to examine key health indicators-such as metabolic, hormonal, and cardiovascular markers-with reliable, lab-grade testing kits at home.
Key trends fostering development in this area include the growing focus on preventive healthcare. Demand from high diabetes and heart disease prevalence areas drives this trend.
Advancements in biomarker detection technology, especially immunoassays like ELISA, have been credited with having improved specificity alongside cost reduction.
Advanced At-Home Biomarker Testing Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 1,024.0 million |
| Estimated Size, 2024 | USD 1,099.5 million |
| Projected Size, 2034 | USD 2,255.7 million |
| Value-based CAGR (2024 to 2034) | 7.5% |
Targeted therapies, also referred to as precision or personalized medicine, are meant to specifically attack disease processes or cells with minimal invasion of healthy tissues.
Biomarkers, measurable biological indicators used for identification and characterization of specific disease characteristics and patient phenotypes, form the guiding backbone for the application of targeted therapies. Therefore, biomarker testing forms a crucial component in ensuring the efficacy of these treatments.
There is an increased market growth of biomarker testing caused by the ascending rates of targeted therapies.
Traditional therapies such as chemotherapy of cancer, and immunosuppressive drugs for autoimmune diseases may have significant side effects because they do not distinguish between the healthy cells and diseased cell.
On the other hand, targeted therapies work directly on particular molecules or pathways directly involved in the disease with simultaneous better efficiency and less toxicity.
There are also opportunities for biomarkers in the identification of predictive biomarkers for treatment. For example, HER2 breast cancer, EGFR mutations, and PD-L1 are in oncology used to select patients who are targeted for therapy with targeted agents like trastuzumab, gefitinib, and pembrolizumab.
Increased biomarker test accuracies with the advent of more targeted therapies for certain genetic or molecular characteristics are opening new areas in the market. Overall, biomarker testing market is highly driven by the demand for targeted therapies in cancer and autoimmune diseases.
Biomarkers play an important role in the right decision-making regarding the choice of patients, treatment of patients, appropriate monitoring of treatment efficacy, and resistance detection.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Adoption of Point-of-care Diagnostics in Home Care Settings Driving Market Growth
Patients are developing interest in managing sessions and programs for their health, with little intervention from clinical or hospital experts. Interest in preventive health is driving increased demand and ideas for At-home testing.
Existing at-home biomarker testing is the driving factor for this opportunity, providing the ability to monitor many health indicators at home: glucose levels, cholesterol, hormone levels, and even cancer markers.
The simplicity and results given immediately at the point of care without extensive laboratory involvement make home-based health care seem remarkably appealing.
For instance, Microfluidics refers to the flow of small volumes of fluids, usually in channels as small as a human hair thickness, which is critical for lab-on-a-chip (LOC) devices. LOC devices consolidate multiple laboratory functions on a single chip providing quick and suitable procedures for biomarker analysis from minimal blood, saliva, or urine samples.
These devices can conduct very complicated diagnostic tests in less than complete minutes, thus providing lab-quality results in the home environment. In the end, therefore, we see home care use of point-of-care diagnostics as a major factor favoring growth within the advanced at-home biomarker testing market.
The Market Is Experiencing Significant Growth Due to the Regulatory Support and Fast-track Approvals
The regulatory support and fast-track approval through the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have gained prominence to be the advanced at home biomarker testing market drivers.
Such regulatory body roles provide safety, accuracy, and efficacy of diagnostic tools, especially those used outside of conventional healthcare settings.
Regulatory agencies expedite the development and market entry of at-home biomarker tests through streamlined approval processes and the creation of a clear roadmap for manufacturers, while at the same time fulfilling the increasing demand for convenient, accessible, and personalized healthcare by consumers. For instance, In January 2022, 23andMe Holding Co. received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker.
The fast-track approval mechanisms introduced by the FDA and EMA facilitate the rapid clinical evaluation and approval of diagnostic devices, especially for those targeting urgent or unmet medical needs.
This pathway is extremely important for the at-home biomarker testing market because it helps manufacturers to introduce innovative products in the market faster but ensures that they conform to necessary safety and performance standards.
Increasing Focus on Early Disease Detection for Advanced At-Home Biomarker Testing Market is emerging as Significant Opportunity for the Market
Besides the early detection of diseases for improving prognosis and chances of successful treatment, conditions such as cancers, cardiovascular disease, diabetes, and autoimmune disorders often do not show symptoms until they are far along in their development.
Once the symptoms become apparent, treatment is then wedge in through with a less effectiveness than before when the disease was still manageable and in an advanced stage. Early detection, therefore, comes with timely intervention, oftentimes yielding better results, less invasive treatments, and even less cost to healthcare.
For instance, liquid biopsy technology is developed for the detection of tumor biomarkers, such as ctDNA in the blood. These tests find minimal amounts of cancerous genetic material, thus enabling diagnosis well in advance of a tumor becoming large enough to be identified with imaging techniques.
In this way, risks from cardiovascular diseases have also been noticed through early measurement of biomarkers, including C-reactive protein-a marker of inflammation that often precedes the incidence of heart attack.
Liquid biopsy approaches may detect cancer biomarkers, such as those circulating in the blood. For instance, tests can reveal tiny amounts of cancer-related genetic material that enable diagnoses years earlier than is possible with tumor imaging techniques.
On a similar note, risks of heart-related diseases may be identified early on by the use of biomarkers, such as C-reactive protein (CRP), inflammatory markers often seen ahead of heart attacks or strokes.
Risk of Improper Sample Collection or Handling by Users May Restrict Market Growth
The convenience of at-home testing brings on another problem which is the most critical tasks of sample collection and handling are transferred from the trained hands of healthcare professionals to untrained consumers. All other forms of poor collection or biological sample mishandling, such as blood, saliva, and urine, result in faulty test results and false positives or negatives with misdiagnosis or delayed treatment.
This risk not only threatens the effectiveness of biomarker testing but also fosters a more general problem of growth in this market and its consumer adoption.
Biomarker testing, done at home, requires sample collection by the patients themselves. Such a collection would have normally fallen within the domain of a medical professional in a clinical setting. The samples usually collected are blood via finger pricks, urine, or saliva. Although the process does appear to be, relatively simple, correct technique is required for an accurate result.
Most consumers lack any type of medical training that is necessary to ensure samples are collected in a manner that will support an appropriate result. The test is sensitive to technical errors or poor collection of samples; hence, it will yield a biased result.
In conclusion, while at-home biomarker testing offers convenience, it presents a significant challenge due to the complexity of proper sample collection and handling. The transfer of this responsibility from trained healthcare professionals to untrained consumers increases the risk of errors, leading to inaccurate results, misdiagnoses, and delayed treatments.
The global advanced at-home biomarker testing industry recorded a CAGR of 5.3% during the historical period between 2019 and 2023. The growth of advanced at-home biomarker testing industry was positive as it reached a value of USD 2,255.7 million in 2034 from USD 1,099.5 million in 2024.
The shift has been rapid, from simple home health tests to advanced, lab-quality diagnostics that offer in-depth health insights. Traditional at-home health testing was confined to very simple metrics such as glucose, pregnancy tests, and other specific health needs.
With new developments in technology and data analytics, the market today covers a wide spectrum of biomarkers, ranging from metabolic, hormonal, and cardiovascular to genetic indicators.
Today, increasing interest in preventive health, better chronic disease management, and personalized wellness drives demand for biomarker testing from the comfort of one's own home.
Today, users have direct access to reliable results through user-friendly testing kits, with actionable insights provided through digital platforms that enable health monitoring without clinical visits. This suggests a larger trend toward digital health solutions and positions at-home biomarker testing at the forefront of personalized healthcare and an up-and-coming self-care movement.
Principal Consultant
Tier 1 companies dominate the market, gaining the highest share from their superior technological offerings and massive investments in R&D, capturing significant market share of 63.6% in global market.
Some of the noted players in this tier include Quest Diagnostics, Laboratory Corporation of America® Holdings, 23andMe, Inc.
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 22.2% market share. One of the most important companies in this category is Everlywell, Inc., PrivaPath Diagnostics (LetsGetChecked), Vir Health Limited, Gene by Gene, Ltd. and Home Test Box.
Finally, Tier 3 companies, such as BioSure Global Ltd, YorkTest, Healthy Human Labs LTD (Vitall), myLAB Box among others are essential for the market, and holds around 14.1% market share.
The section below covers the industry analysis for the advanced at-home biomarker testing market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 4.0% through 2034. In Asia Pacific, China is projected to witness a CAGR of 13.1% by 2034.
| Country | Value CAGR (2024 to 2034) |
|---|---|
| United States | 4.0% |
| Germany | 6.1% |
| France | 7.5% |
| UK | 8.8% |
| China | 13.1% |
| India | 8.6% |
Germany’s advanced at-home biomarker testing market is expected to exhibit a CAGR of 6.1% between 2024 and 2034. The Germany holds highest market share in European market.
Increased health awareness, a strong prevention orientation, and a well-grounded structure of healthcare, fosters further growth of the advanced at-home testing market in Germany.
Germans are becoming increasingly proactive with regard to dealing with their health problems by seeking personalized insights into biomarkers. Moreover, the spread of chronic diseases, including diabetes and cardiovascular conditions, has strengthened demand for accessible at-home options.
German healthcare policies favor digital health innovations. Initiatives toward patient empowerment and self-management will align well with the adoption of at-home testing.
With ongoing development in diagnostic technologies, coupled with a preference for quality healthcare solutions, making consumers look for convenient and reliable means to monitor their health out of traditional clinical settings, the outlook for growth in the German market is bright.
United States market is anticipated to grow at a CAGR of 1.7% throughout the forecast period. In the United States market, the advanced at-home testing market is guided by a strong shift towards preventive care, convenience, and personalized health management.
The rising prevalence of diabetes or heart diseases have increased the demand for at-home testing, as more people are in search of tools for monitoring health status. On the consumer front, they appreciate the convenience and privacy that at-home test kits provide in addition to online result availability.
Innovations related to biomarker testing, along with supportive regulatory measures, have made viable the provision of high-quality at-home test kits, whereas the country's digital health ecosystem accelerates acceptance.
Further, the growing health-conscious population guiding a lifestyle-related disease epidemic is ramping up demand for these various tests, resulting in the United States being among the top-leading countries applying advanced at-home biomarker solutions.
India is expected to hold dominating position in East Asia market of advanced at-home biomarker testing and is anticipated to grow at a CAGR of 8.6% throughout the forecast period.
There's wide scope of growth for the at-home testing market in India. Its advanced rise is evident due to an increase in awareness about health, the supporting middle class, and increased illness caused by lifestyle changes like diabetes and hypertension.
As rural and urban areas are not willing to spend money on access to mainstream healthcare, at-home testing offers millions of Indians, the best means of action that is affordable to them.
Widespread adoption of digital health platforms further boosts acceptance of home-test kits. COVID-19 further increased the demand for remote health solutions, paving the way for a shift in how Indians view regular health checkups. With government initiatives regularly promoting healthcare innovation and prevention, the home testing biomarker market is poised for huge growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section contains information about the leading segments in the industry. Based on biomarker type, metabolic biomarkers are expected to account for 22.3% of the global market share in 2024.
| Biomarker type | Metabolic Biomarkers |
|---|---|
| Value Share (2024) | 22.3% |
Within the advanced at-home biomarker testing market, metabolic biomarkers are dominating, as they represent important indicators for overall health, chronic disease risk, and risk due to lifestyle-related conditions. These biomarkers for example, refer to blood glucose, cholesterol, and triglycerides, being invaluable for their indication in terms of metabolic health.
Early symptoms of diabetes, cardiovascular diseases, and obesity-all highly prevalent worldwide-are indicated by these biomarkers.
Emphasis on metabolic biomarkers closely monitors the growing focus on prevention and management of chronic disease. Proper recognition and monitoring would reduce healthcare expenditure and lead to better outcomes in general.
| Technology | Immunoassays (ELISA) |
|---|---|
| Value Share (2024) | 27.9% |
The immunoassays are the dominating, with ELISA leading the front due to their reliability, sensitivity, and adaptability for a wide range of biomarker types. For this reason, ELISA technology is able to accurately detect low levels of biomarkers, making it perfect for identifying certain proteins, hormones, and antibodies relevant to metabolic disorders, infections, and hormonal imbalances.
Sensitivity is an important requirement in out-of-clinic testing, where a reliable result is paramount for the consumer.
The wide adaptability to biomarkers of different natures makes ELISA able to cover everything from metabolic and hormone markers to immune response indicators in at-home testing kits. This allows companies to have one technology across multiple tests, streamlining production and reducing costs.
The advanced at-home biomarker testing market is highly competitive with many key players actively working hard to both maintain and even enhance their market positions.
Major players in this industry are concentrating on innovation, investing highly in more advanced technologies and applications to cater for different needs healthcare providers and patients have. Such strategic approaches include forming strategic partnerships, mergers, and acquisitions to expand the product portfolios and geographic reach of such companies.
Recent Industry Developments in Advanced At-home Biomarker Testing Market
In terms of biomarker type, the industry is divided into Genetic Biomarkers (Direct-to-Consumer (DTC) Genetic Testing Kits) (Pharmacogenetics Tests, Carrier Screening Tests, Genetic Health Risk (GHR) Tests, Cancer Predisposition Tests and Low-Risk General Wellness Tests), Metabolic Biomarkers (HbA1c Kits, Cholesterol & Lipid Testing Kits, Insulin Resistance Test Kits and Comprehensive Metabolic Testing Kits), Hormonal Biomarkers (Cortisol Testing Kits, Testosterone & Estrogen Testing Kits, Thyroid Hormones Testing Kits), Inflammatory Biomarkers (C-reactive Protein (CRP) Testing Kit, Vitamin D Testing Kits, Cellular Inflammation Testing Kits), Cancer Biomarkers (Colon Cancer Screening Kits, Prostate Cancer Screening Kits, BRCA1/BRCA2 Mutations), Infectious Disease Biomarkers (HIV and Hepatitis C Antibodies, Herpes, Syphilis and Antimicrobial Resistance Markers), Gut Microbiome Biomarkers (Short Chain Fatty Acids (SCFAs), Gut Dysbiosis Markers), Fertility and Pregnancy Biomarkers (Anti-Müllerian Hormone (AMH), Follicle Stimulating Hormone (FSH) & Luteinizing Hormone (LH), Progesterone), Nutritional Biomarkers and Neurological Biomarkers
In terms of technology, the industry is divided into Immunoassays (ELISA), Lateral Flow Assays (LFA), Biosensors, Colorimetric Tests, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS) and Microfluidics.
In terms of sample type, the industry is divided into Blood, Saliva, Urine, Buccal Swab, and Stool among others.
In terms of disease indication, the industry is divided into Cardiovascular Diseases, Diabetes and Metabolic Disorders, Cancer (Oncology), Infectious Diseases, Hormonal Disorders (Endocrinology), Autoimmune Diseases, Kidney Diseases, Respiratory Diseases, Genetic Disorders, Mental Health and Neurological Disorders.
In terms of delivery format, the industry is divided into Test Kits with Self-Collection (Return to Lab) and Instant At-Home Test Kits.
In terms of distribution channel, the industry is divided into Online Retailers (E-commerce Platforms and Specialized Healthcare Platforms), Retail Pharmacies, and Health Product Stores.
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
The global advanced at-home biomarker testing industry is projected to witness CAGR of 7.5% between 2024 and 2034.
The global advanced at-home biomarker testing industry stood at USD 1,024.0 million in 2023.
The global advanced at-home biomarker testing industry is anticipated to reach USD 2,255.7 million by 2034 end.
France is expected to show a CAGR of 7.5% in the assessment period.
The key players operating in the global advanced at-home biomarker testing industry include Quest Diagnostics, Laboratory Corporation of America® Holdings, Everlywell, Inc., 23andMe, Inc., Gene by Gene, Ltd., MyDiagnostics, HelloMe, Imaware, NiaHealth, PrivaPath Diagnostics (LetsGetChecked), BioSure Global Ltd, YorkTest, Lifelab TestingTM, Chronomics Limited, Healthy Human Labs LTD (Vitall), Vir Health Limited, ZoomDoc, Home Test Box, Zone Labs Inc., Verisana Laboratories, Personal Diagnostics L
Explore Healthcare Insights
View Reports
Advanced At-home Biomarker Testing Market
